Medications, based on psychedelic substances that manage inflammation, could potentially serve a broader population than mental health treatments.
In the late 1980s, the number of research papers in psychedelic science were less than two dozen annually. Last year saw over 600 published.
TDR sits down with Derek Welsh, Founder of Psilocin and COO of Psilocin Pharma to discuss the potential of psychedelics and how it’s nasty stigma has hindered.
When something is psychedelic as f–k, it’s a moment that helps define the vague notion of what exactly the psychedelic, IS.
We can look around today and see many psychedelic business models. But what we really need are psychedelic models for business...
ATAI Life Sciences acquires majority stake in New York pharmaceutical company Kures to target the important intersection between pain and opioid use disorder.
Peyote is on the brink of extinction, and numbers of poachers are on the rise.
Welcome to TDR’s review of the Top 5 psychedelic stories of the past week.
.png)
.png)
